BrightGene Bio-Medical Technology Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 914.88 million compared to CNY 772.32 million a year ago. Revenue was CNY 914.88 million compared to CNY 772.32 million a year ago.

Net income was CNY 191.79 million compared to CNY 197.62 million a year ago. Basic earnings per share from continuing operations was CNY 0.45 compared to CNY 0.48 a year ago. Diluted earnings per share from continuing operations was CNY 0.45 compared to CNY 0.48 a year ago.